Bifogade filer
Invitation to presentation of Xbrane Biopharma’s interim report January – September 2024 on October 24, 2024
Kurs
+19,44%
Likviditet
13,2 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-05-08 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-05 | - | Årsstämma |
| 2025-02-21 | 08:00 | Bokslutskommuniké 2024 |
| 2024-10-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-03 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2024-05-02 | - | Årsstämma |
| 2024-02-26 | - | Bokslutskommuniké 2023 |
| 2024-02-22 | - | Extra Bolagsstämma 2024 |
| 2023-11-30 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-31 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-10-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-22 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-05-05 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | Bokslutskommuniké 2021 |
| 2021-10-29 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-13 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-07 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2021-05-06 | - | Årsstämma |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-22 | - | Extra Bolagsstämma 2020 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-22 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2020-06-18 | - | Årsstämma |
| 2020-05-14 | - | Årsstämma |
| 2020-05-13 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-28 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-23 | - | Kvartalsrapport 2019-Q2 |
| 2019-06-18 | - | Extra Bolagsstämma 2019 |
| 2019-05-17 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-14 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-24 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-25 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2018-05-14 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-03 | - | Extra Bolagsstämma 2018 |
| 2018-02-28 | - | Bokslutskommuniké 2017 |
| 2017-11-13 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-19 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2017-05-18 | - | Årsstämma |
| 2017-05-18 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-07 | - | Kapitalmarknadsdag 2017 |
| 2017-02-27 | - | Bokslutskommuniké 2016 |
| 2016-11-21 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-22 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-27 | - | Kvartalsrapport 2016-Q1 |
| 2016-05-27 | - | X-dag ordinarie utdelning XBRANE 0.00 SEK |
| 2016-05-26 | - | Årsstämma |
| 2016-02-18 | - | Bokslutskommuniké 2015 |
| 2015-10-23 | - | Kvartalsrapport 2015-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Thursday, October 24th, 2024, at 13.00 a.m. CET. Xbrane will publish the company’s interim report January – September 2024, on Thursday, October 24, 2024, at 8.00 a.m. CET.
Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – September 2024, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:
If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions.
Xbrane Biopharma Q3 Report 2024 (financialhearings.com)
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
Contacts
Martin Åmark, CEO
E: martin.amark@xbrane.com
Anette Lindqvist, CFO/IR
E: anette.lindqvist@xbrane.com
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com